Electrovaporization is a new and potentially useful modification of transurethral resection of the prostate which is rapidly becoming a treatment of choice for symptomatic benign prostatic hyperplasia. We report our experience with 22 patients treated using the Circon Acmi Grooved Vaportrode vaporization electrode. Procedures were carried out using the standard technique of electrovaporization with general or regional anaesthesia. Mean operative time was 40 minutes (range 25-65 minutes) and all patients were discharged without catheter after 1 or 2 days. Symptom score, peak uroflow and postvoid residual urine showed statistically significant improvement at 3 months (p < 0.01). There were no significant complications. Transurethral electrovaporization of the prostate seems to be a easy and safe procedure with significantly lower costs and excellent results. However, long-term efficacy and complications need to be evaluated in multicentre clinical trials.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of PKRP and TUVP in the treatment of high-risk BPH and analysis of postoperative influencing factors.
Front Surg
August 2022
Department of Urology Surgery, Shunyi Hospital, Beijing, China.
Objective: This study aims to compare the efficacy of plasma kinetic loop resection of the prostate (PKRP) and transurethral vaporization of the prostate (TUVP) for the treatment of high-risk benign prostatic hyperplasia (BPH), and analyze the influence of the related factors on the operation of BPH.
Methods: A total of 108 high-risk BPH patients diagnosed in our hospital from March 2018 to September 2021 were selected and randomly divided into an observation group and a control group, with 54 cases in each group. The control group was treated with TUVP, and the observation group was treated with PKRP.
Recent advances in prostatectomy for benign prostatic hyperplasia.
F1000Res
May 2020
Weill Medical College of Cornell University, Ithaca, NY, USA.
This review provides a brief overview of and commentary on currently available technology for the surgical treatment of obstructive benign prostatic hyperplasia causing lower urinary tract symptoms. This review provides references relevant to review and understand current technology that is clinically available.
View Article and Find Full Text PDFPure Bipolar Plasma Vaporization of the Prostate: Results from a Prospective 3D Ultrasound Volumetry Study with Clinical Outcome After 3 Years.
J Endourol
February 2019
Department of Urology, University Hospital Zürich, University of Zürich, Zürich Switzerland.
Introduction And Objectives: Bipolar plasma vaporization (BPV) has been shown to be a low-morbidity alternative to conventional transurethral resection of the prostate (TURP). Improved functional short-term outcome and a postoperative prostate volume reduction comparable to TURP have been reported. However, comprehensive mid- or long-term results following BPV are still lacking.
View Article and Find Full Text PDFManagement of greenlight laser plus transurethral resection of prostate for elderly men.
Medicine (Baltimore)
August 2018
Department of Urology, Tianjin Union Medical Center, Hong-qiao District, Tianjin, China.
The study is aiming to evaluate the treatment safety and efficacy of greenlight laser photovaporization of the prostate (PVP) combined with transurethral electrovaporization resection (TUVP) for elderly (≥ 70 years) men with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH/LUTS) with a large prostate volume (≥ 80 mL). One hundred twelve BPH/LUTS patients treated with PVP were divided into 2 groups according to prostate volume (PV), the outcomes of the 2 groups were assessed at 12 months after the operation. Patients in the PV ≥ 80 group (n = 51) had a higher level of maximum detrusor pressure (Pdet.
View Article and Find Full Text PDFProstate cancer: Basics on clinical appearance, diagnostics and treatment.
Med Monatsschr Pharm
May 2017
With an incidence of approximately 60,000 per year prostate cancer is the most common malignant neoplasm in men with a relatively low mortality rate and a high mean age of primary diagnosis of about 70 years. The disease remains usually clinically occult over a long period of time and generally manifests primarily in a locally advanced or metastasized stage. Due to screening using the PSA level (prostate specific antigen) in blood serum, diagnosis and therapy nowadays are oftentimes possible at an early stage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!